According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

“Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis ... and lower sweat chloride levels than TRIKAFTA, is another step in achieving this goal.” ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

which show that treatment with VRTX's Alyftrek enhances patient benefit compared to the blockbuster drug Trikafta. Vertex has won two cystic fibrosis approvals from the FDA, but the agency ...

Last year Nicole Stringer went from very sick with cystic fibrosis to embracing an exciting, healthy lifestyle because of a new drug called Trikafta. “I was diagnosed with cystic fibrosis when I ...

The company’s product portfolio includes Trikafta, Symdeko/Symkevi, Orkambi (ivacaftor/lumacaftor), and Kalydeco (ivacaftor) for treating cystic fibrosis. Through its research and development efforts, ...

LCI proves valuable in monitoring ETI therapy effectiveness for cystic fibrosis patients with minimal FEV1 changes, detecting ...

NHS England has agreed a deal with Vertex for its three-drug cystic fibrosis therapy Kaftrio, just days after the EMA’s human medicines committee recommended approval of the drug. The deal means ...